Tailored therapy may improve outcomes for frail elderly myeloma patients
NCT ID NCT06099912
First seen Jan 12, 2026 · Last updated Apr 30, 2026 · Updated 15 times
Summary
This study tests a personalized treatment approach for people aged 65 and older who are newly diagnosed with multiple myeloma. The treatment plan is adjusted based on each patient's frailty level, aiming to improve response rates and reduce the chance of stopping treatment due to side effects. About 131 participants will receive a combination of drugs including daratumumab, and researchers will monitor how well the cancer responds and any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Hospital of Jilin University
RECRUITINGChangchun, Jilin, 130021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.